{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031085","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.218639+00:00","generated_at":"2026-06-08T06:32:12.465930+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Atossa Therapeutics appoints Jonathan Finn to board of directors and audit committee","bullets":["Jonathan Finn appointed to board as Class I director and audit committee member, effective November 9, 2023.","Finn succeeds Greg Weaver and will serve until the 2025 Annual Meeting of Stockholders.","Finn brings over 25 years of financial industry experience, focusing on early to mid-stage biotech and tech companies.","Compensation follows standard non-employee director terms as per 2023 proxy; standard indemnification agreement to be entered.","No arrangements, family relationships, or material interests in any transactions requiring disclosure."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031085","json":"https://secwatch.observer/filing/0001437749-23-031085.json","markdown":"https://secwatch.observer/filing/0001437749-23-031085.md","text":"https://secwatch.observer/filing/0001437749-23-031085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923031085/0001437749-23-031085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923031085/atos20231106_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:32:12.465930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24f15884a7","claim":"Jonathan Finn was appointed as Class I Director at ATOSSA THERAPEUTICS, INC..","evidence_excerpt":"Jonathan Finn, CFA, has been appointed to the Company's board of directors, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923031085/0001437749-23-031085-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"f8de39ee4c","claim":"Greg Weaver departed as Class I Director at ATOSSA THERAPEUTICS, INC..","evidence_excerpt":"Mr. Finn succeeded Greg Weaver as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923031085/0001437749-23-031085-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"succeeded"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}